Exploring synergies between B- and T-cell vaccine approaches to optimize immune responses against HIV-workshop report

doi:10.1038/s41541-024-00818-y

. 2024 Feb 21;9(1):39.

doi: 10.1038/s41541-024-00818-y.

Exploring synergies between B- and T-cell vaccine approaches to optimize immune responses against HIV-workshop report

Affiliations

¹ Division of AIDS, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Rockville, MD, USA.
² Yerkes National Primate Research Center, Emory University, Atlanta, GA, USA.
³ Department of Medicine, University of Pennsylvania, Philadelphia, PA, USA.
⁴ Center for Infectious Disease and Vaccine Research, La Jolla Institute for Immunology (LJI), La Jolla, CA, 92037, USA.
⁵ Department of Medicine, Division of Infectious Diseases and Global Public Health, University of California, San Diego (UCSD), La Jolla, CA, USA.
⁶ Division of HIV, Infectious Diseases, and Global Medicine, San Francisco, CA, USA.
⁷ Department of Medicine, University of California at San Francisco, San Francisco, CA, USA.
⁸ Ragon Institute of Mass General, MIT and Harvard, Cambridge, MA, USA.
⁹ Vaccine and Infectious Disease Division, Fred Hutchinson Cancer Research Center, Seattle, WA, USA.
¹⁰ Nuffield Department of Clinical Medicine, University of Oxford, Oxford, UK.
¹¹ Department of Medicine, University of California, San Francisco, CA, USA.
¹² Division of AIDS, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Rockville, MD, USA. pdsouza@niaid.nih.gov.

PMID: 38383616
PMCID: PMC10881492
DOI: 10.1038/s41541-024-00818-y

Exploring synergies between B- and T-cell vaccine approaches to optimize immune responses against HIV-workshop report

Milton Maciel Jr et al. NPJ Vaccines. 2024.

. 2024 Feb 21;9(1):39.

doi: 10.1038/s41541-024-00818-y.

Authors

Affiliations

¹ Division of AIDS, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Rockville, MD, USA.
² Yerkes National Primate Research Center, Emory University, Atlanta, GA, USA.
³ Department of Medicine, University of Pennsylvania, Philadelphia, PA, USA.
⁴ Center for Infectious Disease and Vaccine Research, La Jolla Institute for Immunology (LJI), La Jolla, CA, 92037, USA.
⁵ Department of Medicine, Division of Infectious Diseases and Global Public Health, University of California, San Diego (UCSD), La Jolla, CA, USA.
⁶ Division of HIV, Infectious Diseases, and Global Medicine, San Francisco, CA, USA.
⁷ Department of Medicine, University of California at San Francisco, San Francisco, CA, USA.
⁸ Ragon Institute of Mass General, MIT and Harvard, Cambridge, MA, USA.
⁹ Vaccine and Infectious Disease Division, Fred Hutchinson Cancer Research Center, Seattle, WA, USA.
¹⁰ Nuffield Department of Clinical Medicine, University of Oxford, Oxford, UK.
¹¹ Department of Medicine, University of California, San Francisco, CA, USA.
¹² Division of AIDS, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Rockville, MD, USA. pdsouza@niaid.nih.gov.

PMID: 38383616
PMCID: PMC10881492
DOI: 10.1038/s41541-024-00818-y

Erratum in

Author Correction: Exploring synergies between B- and T-cell vaccine approaches to optimize immune responses against HIV-workshop report.
Maciel M Jr, Amara RR, Bar KJ, Crotty S, Deeks SG, Duplessis C, Gaiha G, McElrath MJ, McMichael A, Palin A, Rutishauser R, Shapiro S, Smiley ST, D'Souza MP. Maciel M Jr, et al. NPJ Vaccines. 2024 Mar 14;9(1):61. doi: 10.1038/s41541-024-00852-w. NPJ Vaccines. 2024. PMID: 38485736 Free PMC article. No abstract available.

Abstract

The US National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institute of Health (NIH), convened a virtual workshop on August 8-9^th, 2023 to explore potential synergies between HIV vaccine approaches that are designed to induce cellular or humoral immune responses. The goal of this workshop was to review data on leading vaccine candidates and to discuss the best strategies for combining these approaches to optimize immunity against HIV. Here, we summarize the findings reviewed at the workshop and discuss the knowledge gaps and priorities for future studies that will help accelerate the development of a preventive HIV vaccine.

PubMed Disclaimer

Conflict of interest statement

The authors declare no competing interests.

Figures

**Fig. 1. Non-human primate studies ongoing at Emory to investigate the mechanisms of collaboration between T and B cell HIV vaccines.**
Schemes were simplified to indicate the products and sequence of immunization; control groups, intervals and doses are not indicated. a Immunizations performed via intramuscular injections; heterologous viral vectors: *VSV* Vesicular Stomatitis virus, VV vaccinia virus, *Ad5* Adenovirus type 5. BG505 SOSIP trimer - stabilized envelope protein (administered with 3M-052-AF+Alum). Red box – simian-human immunodeficiency virus challenges administered intravaginally. b Immunization routes are indicated on the left of each group; heterologous viral vectors: *VSV* Vesicular Stomatitis virus, VV vaccinia virus, *Ad5* Adenovirus type 5, *MVA* modified vaccinia Ankara, *ChAdC6* chimpanzee Adenovirus type C6. 1086c UFO – soluble uncleaved pre-fusion optimized gp140 trimer protein (administered subcutaneously with 3M-052-PLGA nanoparticles). Dotted red boxes - Gag peptide – immunodominant Gag peptide recognized by MAMU-A-1 are delivered vaginally non-traumatically 24 hs prior to tissue collection. Dashed boxes indicate intramuscular administration of the 1086c UFO protein in all groups.

See this image and copyright information in PMC

Cited by

HIV Vaccine Development at a Crossroads: New B and T Cell Approaches.
Govindan R, Stephenson KE. Govindan R, et al. Vaccines (Basel). 2024 Sep 12;12(9):1043. doi: 10.3390/vaccines12091043. Vaccines (Basel). 2024. PMID: 39340073 Free PMC article. Review.
Editorial: Forty Years of Waiting for Prevention and Cure of HIV Infection - Ongoing Challenges and Hopes for Vaccine Development and Overcoming Antiretroviral Drug Resistance.
Parums DV. Parums DV. Med Sci Monit. 2024 Apr 1;30:e944600. doi: 10.12659/MSM.944600. Med Sci Monit. 2024. PMID: 38557932 Free PMC article.
Hepatitis C Virus E1E2 Structure, Diversity, and Implications for Vaccine Development.
Pierce BG, Felbinger N, Metcalf M, Toth EA, Ofek G, Fuerst TR. Pierce BG, et al. Viruses. 2024 May 18;16(5):803. doi: 10.3390/v16050803. Viruses. 2024. PMID: 38793684 Free PMC article. Review.

References

1. Barouch DH, et al. Evaluation of a mosaic HIV-1 vaccine in a multicentre, randomised, double-blind, placebo-controlled, phase 1/2a clinical trial (APPROACH) and in rhesus monkeys (NHP 13-19) Lancet. 2018;392:232–243. doi: 10.1016/S0140-6736(18)31364-3. - DOI - PMC - PubMed
1. Gilbert PB, et al. Statistical interpretation of the RV144 HIV vaccine efficacy trial in Thailand: a case study for statistical issues in efficacy trials. J. Infect. Dis. 2011;203:969–975. doi: 10.1093/infdis/jiq152. - DOI - PMC - PubMed
1. Hammer SM, et al. Efficacy trial of a DNA/rAd5 HIV-1 preventive vaccine. N. Engl. J. Med. 2013;369:2083–2092. doi: 10.1056/NEJMoa1310566. - DOI - PMC - PubMed
1. Haynes BF, et al. Strategies for HIV-1 vaccines that induce broadly neutralizing antibodies. Nat. Rev. Immunol. 2023;23:142–158. doi: 10.1038/s41577-022-00753-w. - DOI - PMC - PubMed
1. Corey L, et al. Two Randomized Trials of Neutralizing Antibodies to Prevent HIV-1 Acquisition. N. Engl. J. Med. 2021;384:1003–1014. doi: 10.1056/NEJMoa2031738. - DOI - PMC - PubMed

LinkOut - more resources

Full Text Sources

[1] Barouch DH, et al. Evaluation of a mosaic HIV-1 vaccine in a multicentre, randomised, double-blind, placebo-controlled, phase 1/2a clinical trial (APPROACH) and in rhesus monkeys (NHP 13-19) Lancet. 2018;392:232–243. doi: 10.1016/S0140-6736(18)31364-3. - DOI - PMC - PubMed

[2] Barouch DH, et al. Evaluation of a mosaic HIV-1 vaccine in a multicentre, randomised, double-blind, placebo-controlled, phase 1/2a clinical trial (APPROACH) and in rhesus monkeys (NHP 13-19) Lancet. 2018;392:232–243. doi: 10.1016/S0140-6736(18)31364-3. - DOI - PMC - PubMed

[3] Gilbert PB, et al. Statistical interpretation of the RV144 HIV vaccine efficacy trial in Thailand: a case study for statistical issues in efficacy trials. J. Infect. Dis. 2011;203:969–975. doi: 10.1093/infdis/jiq152. - DOI - PMC - PubMed

[4] Gilbert PB, et al. Statistical interpretation of the RV144 HIV vaccine efficacy trial in Thailand: a case study for statistical issues in efficacy trials. J. Infect. Dis. 2011;203:969–975. doi: 10.1093/infdis/jiq152. - DOI - PMC - PubMed

[5] Hammer SM, et al. Efficacy trial of a DNA/rAd5 HIV-1 preventive vaccine. N. Engl. J. Med. 2013;369:2083–2092. doi: 10.1056/NEJMoa1310566. - DOI - PMC - PubMed

[6] Hammer SM, et al. Efficacy trial of a DNA/rAd5 HIV-1 preventive vaccine. N. Engl. J. Med. 2013;369:2083–2092. doi: 10.1056/NEJMoa1310566. - DOI - PMC - PubMed

[7] Haynes BF, et al. Strategies for HIV-1 vaccines that induce broadly neutralizing antibodies. Nat. Rev. Immunol. 2023;23:142–158. doi: 10.1038/s41577-022-00753-w. - DOI - PMC - PubMed

[8] Haynes BF, et al. Strategies for HIV-1 vaccines that induce broadly neutralizing antibodies. Nat. Rev. Immunol. 2023;23:142–158. doi: 10.1038/s41577-022-00753-w. - DOI - PMC - PubMed

[9] Corey L, et al. Two Randomized Trials of Neutralizing Antibodies to Prevent HIV-1 Acquisition. N. Engl. J. Med. 2021;384:1003–1014. doi: 10.1056/NEJMoa2031738. - DOI - PMC - PubMed

[10] Corey L, et al. Two Randomized Trials of Neutralizing Antibodies to Prevent HIV-1 Acquisition. N. Engl. J. Med. 2021;384:1003–1014. doi: 10.1056/NEJMoa2031738. - DOI - PMC - PubMed

Save citation to file

Email citation

Add to Collections

Add to My Bibliography

Your saved search

Create a file for external citation management software

Your RSS Feed

Exploring synergies between B- and T-cell vaccine approaches to optimize immune responses against HIV-workshop report

Affiliations

Exploring synergies between B- and T-cell vaccine approaches to optimize immune responses against HIV-workshop report

Authors

Affiliations

Erratum in

Abstract

Conflict of interest statement

Figures

Similar articles

Cited by

References

LinkOut - more resources

Full Text Sources

Erratum in

Abstract

Conflict of interest statement

Figures

Similar articles

Cited by

References

Related information

LinkOut - more resources

Full Text Sources